1. Pfizer surged 15% last week due to positive news, including a direct-to-consumer deal and tariff relief; 2. The stock offers a high 6.28% dividend yield with a safe payout ratio and attractive valuation (forward PE of 8.87); 3. Technical indicators show bullish momentum, strong institutional buying, and potential for further upside if price breaks consolidation levels.